

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 September 2023 (28.09.2023)



(10) International Publication Number
WO 2023/183801 A2

- (51) **International Patent Classification:**
C12N 15/11 (2006.01) A61K 31/712 (2006.01)
- (21) **International Application Number:**
PCT/US2023/064765
- (22) **International Filing Date:**
21 March 2023 (21.03.2023)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/322,845 23 March 2022 (23.03.2022) US
- (71) **Applicant: AMGEN INC.** [US/US]; One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).
- (72) **Inventors: MEADE, Bryan;** One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **MURRAY, Justin K.;** One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **RULIFSON, Ingrid;** One Amgen Center Drive, Law Department-Patent Operations,

Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US). **HOMANN, Oliver;** One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(74) **Agent: KARABINIS, Melissa;** One Amgen Center Drive, Law Department-Patent Operations, Mail Stop 28-5-A, Thousand Oaks, California 91320-1799 (US).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) **Title:** RNAI CONSTRUCTS FOR INHIBITING PNPLA3 EXPRESSION AND METHODS OF USE THEREOF

Figure 1

Duplex No.	PNPLA3 Location	Sense Strand Sequence	Sense Strand SEQ ID NO:	Sense Strand Modified Sequence	Sense Strand Mod SEQ ID NO:	Antisense Strand Sequence	Antisense Strand SEQ ID NO:	Antisense Strand Modified Sequence	Antisense Strand Mod SEQ ID NO:
37555-1	113	AGCUGCUGC GGAUCAGG ACC{invAb}	1069	asgscugcUfgCfGfGf Afucaggaccs{invAb}	1699	AGGUCCUGAU CCGCAGCAGC UUU	2329	asGfsguccUf gaucgcCfGf cagcussus	2959
37556-1	115	CUGCUGCGG AUCAGGACC CG{invAb}	1070	csusgucgCfGfAfUf Cfaggaccgcs{invAb}	1700	UCGGGUCCUG AUCCGCAGCA GUU	2330	usCfsgggguCf cugaucCfGfCf agcagsusu	2960
37557-1	121	CGGAUCAG GACCCGAGC CGA{invAb}	1071	csgsgaucAfGfAfCf Cfagaccgcs{invAb}	1701	AUCGGCUCGG GUCCUGAUCC GUU	2331	asUfscggcUf cgggucCfGf aucgssusu	2961
37558-1	122	GGAUCAGG ACCCGAGCC GAU{invAb}	1072	gsgsaucaGfGfAfCf Cfagaccgcs{invAb}	1702	AAUCGGCUCG GGUCCUGAUC CUU	2332	asAfsucggCf ucggguCfGf gaucussusu	2962
37559-1	204	CAGAGCGCG GCUUGGAGC UUG{invAb}	1073	csasgagcGfGfGfCf Ufaggaccuugs{invAb}	1703	ACAAGCUCCA GCCGCGCUCU GUU	2333	asCfsaagcUf ccagccGfGf cncugssusu	2963
37560-1	205	AGAGCGCG GCUUGGAGC UUGU{invAb}	1074	asgsagcgCfGfCfUf Gfaggaccuugs{invAb}	1704	AACAAGCUCC AGCCGCGCUC UUU	2334	asAfsaagCf uccagcCfGf gcucussusu	2964
37561-1	206	GAGCGCGGC UGGAGCUU GUC{invAb}	1075	gsasgcgcGfGfCfUf Gfaggaccuugs{invAb}	1705	AGACAAGCUC CAGCCGCGCU CUU	2335	asGfsacaaGf cuccagCfGf cgucussusu	2965

(57) **Abstract:** The disclosure relates to RNAi constructs, such as siRNA, for reducing expression of the PNPLA3 gene. Methods of using such RNAi constructs to treat or prevent liver disease, such as nonalcoholic fatty liver disease (NAFLD), are also described.

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*
- *with sequence listing part of description (Rule 5.2(a))*